Anemias of Chronic Disease and Sideroblastic Anemia

Understanding why a patient is anemic requires looking beyond simple nutrient deficiencies. Two critical categories of anemia—anemia of chronic disease (ACD) and sideroblastic anemia—involve profound disruptions in the body's ability to use iron properly, not just acquire it. While both can present with microcytic or normocytic red blood cells, their underlying mechanisms, diagnostic hallmarks, and management strategies are distinct. Mastering these conditions is essential for clinical reasoning, especially when differentiating them from the more common iron deficiency anemia, a frequent point of confusion on exams like the MCAT and in clinical practice.

The Pathophysiology of Anemia of Chronic Disease

Anemia of chronic disease, also called anemia of inflammation, is the second most common anemia worldwide after iron deficiency. It is not a primary hematologic disorder but a consequence of an underlying chronic inflammatory state, such as autoimmune diseases (e.g., rheumatoid arthritis, lupus), chronic infections (e.g., tuberculosis, osteomyelitis), or malignancies. The central player in ACD is hepcidin, a liver-produced peptide hormone that acts as the master regulator of systemic iron homeostasis.

During inflammation, pro-inflammatory cytokines like interleukin-6 (IL-6) trigger a significant increase in hepcidin production. Hepcidin binds to the cellular iron exporter ferroportin, located on the surface of enterocytes (intestinal cells) and macrophages, causing its internalization and degradation. This has two major effects: it blocks dietary iron absorption in the duodenum and, more critically, it traps iron within tissue macrophages of the reticuloendothelial system. This functional iron sequestration creates a state of relative iron deficiency within the bloodstream despite normal or increased total body iron stores. The bone marrow, starved of the iron it needs for hemoglobin synthesis, produces fewer and sometimes smaller red blood cells. Additionally, inflammation directly suppresses erythropoietin production and the bone marrow's response to it, further curtailing red cell production.

Diagnostic Lab Findings in Anemia of Chronic Disease

The laboratory profile of ACD is a key differentiator and a classic exam topic. It reflects the paradoxical state of adequate iron stores but poor iron availability. The hallmark pattern is a low serum iron level coupled with a low total iron-binding capacity (TIBC). TIBC is an indirect measure of circulating transferrin, the protein that transports iron; inflammation suppresses transferrin synthesis. Conversely, ferritin, the intracellular iron storage protein, is an acute-phase reactant. Its levels are elevated both due to inflammation and because iron is being stored, not released. Therefore, elevated serum ferritin is a critical finding that distinguishes ACD from true iron deficiency anemia (where ferritin is low). In practice, a ferritin level above 100 ng/mL generally rules out concomitant iron deficiency in the setting of inflammation, though some guidelines suggest a higher cutoff (e.g., 200 ng/mL). The anemia itself is typically normocytic and normochromic but can become microcytic in long-standing, severe cases.

Mechanisms and Morphology of Sideroblastic Anemia

Sideroblastic anemia represents a direct failure of heme synthesis within the bone marrow's erythroid precursors. The root cause is a defect in the enzymatic pathway that produces heme, the iron-containing component of hemoglobin. This defect leads to ineffective erythropoiesis and the pathological accumulation of non-heme iron in the mitochondria of developing red blood cells. The definitive diagnostic feature is the presence of ringed sideroblasts on a bone marrow aspirate stained with Prussian blue (an iron-specific stain). Under the microscope, these abnormal precursor cells show a ring of blue-staining iron granules circling the nucleus, representing iron-loaded mitochondria. This is distinct from the normal, scattered iron granules seen in other cells.

The impaired heme synthesis results in under-hemoglobinized (hypochromic) red blood cells, leading to a microcytic anemia. However, because the body still absorbs and stores iron normally—it just can't incorporate it into heme—iron studies show a pattern opposite to ACD: high serum iron, high transferrin saturation, and elevated ferritin. The TIBC may be normal or low. This combination of microcytic anemia with evidence of iron overload is a major clue pointing toward sideroblastic anemia.

Etiologies and Management Approaches

The causes of sideroblastic anemia are categorized as hereditary or acquired, and identifying the cause is paramount for treatment. A classic MCAT and clinical association is lead poisoning. Lead inhibits two key enzymes in the heme pathway: aminolevulinic acid dehydratase and ferrochelatase. Another major cause is a deficiency in vitamin B6 (pyridoxine), a crucial cofactor for the first enzyme in heme synthesis, aminolevulinic acid synthase. This deficiency can be nutritional or, famously, induced by the anti-tuberculosis drug isoniazid, which acts as a B6 antagonist. Many cases, particularly in older adults, fall under the umbrella of myelodysplastic syndrome (MDS), a clonal disorder of the bone marrow where acquired genetic mutations disrupt normal hematopoiesis and can lead to ringed sideroblasts.

Management is cause-directed. For drug-induced cases (e.g., isoniazid), removing the offending agent and administering pyridoxine supplementation is key. Patients on isoniazid routinely receive prophylactic B6 to prevent this complication. Hereditary forms may respond to high-dose pyridoxine. For lead poisoning, chelation therapy is required. In MDS-related sideroblastic anemia, treatment focuses on the underlying dysplasia and may include supportive care with erythropoiesis-stimulating agents or, in higher-risk cases, hypomethylating agents. In contrast, the management of anemia of chronic disease centers on treating the underlying inflammatory disorder. If the inflammation is controlled, the anemia often improves. Iron supplementation is typically ineffective and can be harmful unless true concomitant iron deficiency is confirmed. In severe, symptomatic cases, erythropoiesis-stimulating agents may be considered with great caution.

Common Pitfalls

1. Misinterpreting Iron Studies: The most common error is confusing ACD with iron deficiency anemia based solely on a low serum iron level. Always pair this with TIBC and ferritin. Remember the mnemonic: in Iron deficiency, everything is Low (Fe, TIBC/Transferrin saturation, Ferritin). In ACD, Iron is Low, TIBC is Low, and Ferritin is High.
2. Overlooking Mixed Anemias: Patients with chronic inflammatory conditions can also develop true iron deficiency (e.g., from GI blood loss in rheumatoid arthritis patients on NSAIDs). This creates a challenging mixed picture. A ferritin level is the best initial test, but in inflammation, a value below 100-200 ng/mL should raise suspicion for combined deficiency. A bone marrow biopsy showing absent iron stores is definitive.
3. Assuming Microcytosis Equals Iron Deficiency: When you see a microcytic anemia, your differential must include not just iron deficiency, but also ACD (in long-standing cases), sideroblastic anemia, and thalassemia. Jumping immediately to iron supplementation without confirming the etiology can delay correct diagnosis, especially of a condition like MDS.
4. Forgetting the Prussian Blue Stain: The diagnosis of sideroblastic anemia is morphologic. Ordering iron studies alone will show iron overload but will not confirm the diagnosis. The visualization of ringed sideroblasts on a bone marrow biopsy with Prussian blue staining is the diagnostic gold standard.

Summary

• Anemia of chronic disease is an immune-mediated disorder driven by inflammation-induced hepcidin, which causes functional iron sequestration in macrophages, leading to a normocytic/microcytic anemia with a distinctive lab triad: low serum iron, low TIBC, and elevated ferritin.
• Sideroblastic anemia results from defective intramitochondrial heme synthesis, causing iron accumulation and the formation of ringed sideroblasts visible on bone marrow Prussian blue stain. It causes a microcytic anemia with biochemical evidence of iron overload (high serum iron, high ferritin).
• Key etiologies of sideroblastic anemia include lead poisoning (inhibits heme enzymes), vitamin B6 deficiency, the drug isoniazid, and myelodysplastic syndrome.
• Treatment is etiology-specific: address the underlying inflammation for ACD, and use pyridoxine (for deficiency/isoniazid), chelation (for lead), or MDS-directed therapy for sideroblastic anemia.
• Always differentiate these conditions from iron deficiency anemia using the full iron panel (iron, TIBC, ferritin) and consider mixed etiologies in complex patients.